3.229.124.74
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Neurology

TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting

Posted on March 11, 2020

TG Therapeutics, Inc announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS), have been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held April 25 – May 1, 2020, in Toronto, Canada. Abstracts are now available online and can be accessed via the below links or on the AAN meeting website at www.aan.com.

Oral Presentation

Title:Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS

  • Presentation Date & Time: Sunday, April 26, 2020; 1:48 PM ET
  • Session Name: S5: Multiple Sclerosis: Clinical Trials and Disease-modifying Therapy
  • Presentation Number: 003
  • Lead Author: Edward Fox, MD, PhD, Central Texas Neurology Consultants, Round Rock, TX
  • Abstract Number: 1167

Poster Presentation

Title:Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

  • Presentation Date & Time: Tuesday, April 28, 2020; 8:00 – 9:00 AM ET
  • Session Title: Poster Session P8
  • Presentation Number: 019
  • Lead Author: Lawrence Steinman, MD, Stanford University, Stanford, CA
  • Abstract Number: 4845

Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.

Read the full press release here.

Source: TG Therapeutics, Inc
-Advertisement-
Related Articles
Potential Therapy for Rare Neurologic Disease
Apr 06, 2020
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)
Mar 16, 2020
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers
Mar 11, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-